Goldman, 397 patient HCQ late treatment study: 22% lower mortality [p=0.46] https://c19p.org/goldmanh
copied to clipboard
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
et al., NEJM, doi:10.1056/NEJMoa2015301
Study focused on remdesivir but with results for HCQ in the supplementary appendix, showing 9% death with HCQ versus 12% control, unadjusted relative risk uRR 0.78, p = 0.46.
|
risk of death, 22.3% lower, RR 0.78, p = 0.46, treatment 10 of 109 (9.2%), control 34 of 288 (11.8%), NNT 38.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Goldman et al., 5/27/2020, retrospective, multiple countries, multiple regions, peer-reviewed, 26 authors.
Late treatment
is less effective
is less effective
goldman
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.